Improving T-cell therapies for cancer treatment
MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER
This study is looking at ways to make CAR T-cell therapy work better for cancer patients by removing a protein that stops T-cells from fighting tumors, which could help those with tough-to-treat cancers have better results.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11065488 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of adoptive T-cell therapies, particularly chimeric antigen receptor T cells (CAR T cells), for treating cancer. The approach involves investigating the role of the CD5 protein, which inhibits T-cell activation, to improve the anti-tumor response. By using advanced techniques like CRISPR-Cas9 to delete CD5, the researchers aim to boost T-cell signaling and increase the ability of these engineered cells to kill cancer cells. This could lead to better outcomes for patients with difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with refractory CD19+ B cell malignancies or those with solid tumors who have not responded to existing therapies.
Not a fit: Patients with early-stage cancers or those who do not have B cell malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments, providing longer-lasting remissions for patients with B cell malignancies and potentially improving outcomes in solid tumors.
How similar studies have performed: Previous research has shown promise in enhancing T-cell therapies, but this specific approach targeting CD5 is relatively novel and has not been extensively tested.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Ruella, Marco — University of Pennsylvania
- Study coordinator: Ruella, Marco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.